GlassScriptPhysician profile
Anna M Herring
NPI 1861420101
$7,254.92
in general payments reported to CMS, 2019-2025
41 companies · $1,432 in 2025
The $1,432 reported for 2025 was more than what 88% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,173 · 2022: $1,101 · 2023: $1,395 · 2024: $2,154 · 2025: $1,432.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,981.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,980.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,095.98 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $1,047.82 | 2021-2025 | |
| Amgen INC. | $706.05 | 2021-2025 | Otezla, Repatha, Repatha |
| Lilly USA, LLC | $495.54 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $409.44 | 2021-2025 | |
| Astellas Pharma US INC | $336.46 | 2021-2025 | Veozah, Myrbetriq |
| Janssen Pharmaceuticals, INC | $329.47 | 2021-2025 | Xarelto, Spravato |
| Abbott Laboratories | $297.77 | 2022-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Astrazeneca Pharmaceuticals LP | $263.95 | 2021-2024 | Farxiga, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $233.99 | 2021-2025 | Jardiance, Synjardy, Tradjenta |
| Glaxosmithkline, LLC. | $231.73 | 2021-2025 | Trelegy Ellipta, Shingrix |
| Takeda Pharmaceuticals U.S.A., INC. | $208.63 | 2021-2025 | Trintellix |
| Boston Scientific Corporation | $183.27 | 2022-2024 | Wavewriter Alpha Prime 16 |
| Esperion Therapeutics, INC. | $175.84 | 2021-2025 | Nexletol |
| Bayer Healthcare Pharmaceuticals INC. | $155.81 | 2023-2024 |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $149.56 | 2023-2025 | Vyepti |
| E.R. Squibb & Sons, L.L.C. | $104.76 | 2023-2024 | Eliquis |
| Exact Sciences Corporation | $74.12 | 2024-2025 | Cologuard Collection Kit |
| Xeris Pharmaceuticals, INC. | $62.72 | 2023 | Gvoke Hypopen |
| Biohaven Pharmaceutical Holding Company LTD. | $57.68 | 2022 | |
| Ibsa Pharma INC. | $54.21 | 2024 | Tirosint, Licart |
| Shield Therapeutics INC | $53.57 | 2023-2025 | Accrufer |
| Antares Pharma, INC. | $50.32 | 2022-2023 | Tlando, Xyosted, Nocdurna |
| Phathom Pharmaceuticals, INC. | $48.54 | 2024-2025 | Voquezna |
| Eisai INC. | $46.05 | 2022-2024 | |
| Currax Pharmaceuticals LLC | $45.56 | 2023-2024 | Contrave, Nexlizet, Nexletol |
| Acella Pharmaceuticals, LLC | $38.12 | 2024-2025 | NP Thyroid 60 |
| Supernus Pharmaceuticals, INC. | $35.39 | 2021-2024 | Qelbree |
| Allergan, INC. | $29.99 | 2021 | |
| Ascendis Pharma Endocrinology INC | $27.89 | 2025 | Yorvipath |
| Harmony Biosciences LLC | $26.99 | 2025 | |
| Sanofi-Aventis U.S. LLC | $26.18 | 2021-2022 | |
| Axsome Therapeutics, INC. | $21.96 | 2024 | Auvelity |
| Novartis Pharmaceuticals Corporation | $20.12 | 2024 | |
| Corium, LLC | $18.48 | 2023 | Azstarys |
| Clarus Therapeutics INC. | $17.76 | 2021 | |
| Exeltis, USA INC. | $16.59 | 2025 | Slynd |
| Arbor Pharmaceuticals, INC. | $16.42 | 2021 | |
| Sumitomo Pharma America, INC. | $13.69 | 2025 | Gemtesa |
| Idorsia Pharmaceuticals US INC | $13.58 | 2023 | Quviviq |
| Merck Sharp & Dohme LLC | $12.92 | 2023 | Belsomra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Herring listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.